• Recombinant and synthetic nucleic acid molecules (r/sNA), as defined in the NIH Guidelines for Research Involving Recombinant and Synthetic Nucleic Acid Molecules (NIH Guidelines), including gene drive modified organisms (GDMOs)
• Biological Dual Use Research of Concern (DURC)
• Biological toxins
• Microorganisms, including viruses, bacteria, fungi, parasitic agents, and prions that could be harmful to humans, plants, or animals
• Infected research animals
• Genetically engineered models (GEMs)
• Human and non-human primate blood and tissues, and other animal tissues that may present zoonotic and/or other infectious disease concern(s)
• Field research with animals and/or animal specimens known to be reservoirs of zoonotic disease

Submission and Review Process

Activities that require review and approval by the IBC at a fully convened meeting prior to initiation of the research include:

• Research involving r/sNA research that is not exempt from the NIH Guidelines.
• Research requiring biosafety level 3 containment and involving select agents and toxins.
• Any research that is brought to the committee for review.

For research exempted from the NIH Guidelines and requiring biosafety level 1 or 2 are reviewed and approved by the BSO and IBC Chair. These IBC Registrations and amendments that do not require full committee review (FCR), will be placed on the IBC meeting agenda for informational purposes.

Minor changes to an approved IBC Registration can be made and approved by a RIA representative these minor changes include corrections for grammatical errors, typographical errors, addition or removal of personnel (provided that all required training has been completed), and changes in locations (provided that the location is already approved for use of the specific hazard(s))

Proposals to use biological agents in research may be submitted at any time to the IBC. Access eRIA here (Reminder: VPN required to access from off-campus locations)

Proposals received by the submission dates shown below will be reviewed at the next scheduled committee meeting. 

Please contact [email protected] with any questions.